Targeted tumor killing via an intracellular antibody against erbB-2

Area of Science:

• Oncology
• Gene Therapy
• Immunotherapy

Background:

• Overexpression of the erbB-2 oncoprotein drives the growth of certain aggressive tumors, including ovarian carcinoma.
• Targeting erbB-2 is a validated strategy for cancer therapy, but novel delivery methods are needed.
• Intracellular antibodies offer a highly specific mechanism for inhibiting oncoprotein function.

Purpose of the Study:

• To develop and evaluate a gene therapy strategy for targeting erbB-2-overexpressing ovarian cancer.
• To assess the efficacy of a recombinant adenovirus encoding an anti-erbB-2 single-chain antibody for tumor cell killing in vivo.
• To determine the potential of this gene therapy approach for improving survival in ovarian carcinoma models.

Main Methods:

• Construction of a recombinant adenovirus vector encoding an anti-erbB-2 single-chain antibody.
• In vivo administration of the engineered adenovirus into animal models bearing human ovarian carcinoma xenografts.
• Evaluation of tumor cell killing, tumor burden reduction, and animal survival rates.

Main Results:

• The anti-erbB-2 single-chain antibody expressed via adenovirus effectively targeted and killed erbB-2-overexpressing tumor cells.
• Significant prolongation of survival was observed in animals treated with the gene therapy vector compared to control groups.
• The treatment demonstrated high specificity for tumor cells, minimizing off-target effects.

Conclusions:

• Recombinant adenovirus-mediated delivery of an anti-erbB-2 single-chain antibody is a potent strategy for targeted ovarian cancer gene therapy.
• This approach shows significant therapeutic potential, leading to improved survival in preclinical models.
• The findings provide a strong rationale for advancing this gene therapy strategy into human clinical trials for ovarian carcinoma.